COVID-19患者停用与继续使用肾素-血管紧张素系统抑制剂比较(ACEI-COVID):一项前瞻性、平行组、随机、对照、开放标签试验
ACEI-COVID是在奥地利和德国35个中心开展的前瞻性、平行组、随机、对照、开放标签试验,纳入204例近期有症状的SARS-CoV-2感染且长期服用ACEI或ARB的成人患者,1:1随机分为停用组(n=104)和继续组(n=100),干预30天。主要终点30天内最大SOFA评分无显著差异(中位0.00 vs 1.00,p=0.12)。停用组AUCSOFA(0.00 vs 3.50,p=0.040)、平均SOFA评分(0.00 vs 0.12,p=0.040)和30天SOFA评分(0.00 vs 0.00,p=0.023)显著更低。30天时停用组器官功能障碍(SOFA评分≥1)或死亡比例显著更低(11% vs 23%,p=0.017)。机械通气(10% vs 8%,p=0.87)和ICU入住(19% vs 18%,p=0.96)无显著差异。作者认为是否停药应结合风险特征、用药指征、替代治疗及门诊监测条件个体化决定。
要点
- 停用ACEI/ARB对30天最大SOFA评分无显著影响(中位0.00 vs 1.00,p=0.12)。
- 停用组AUCSOFA显著更低(0.00 vs 3.50,p=0.040),平均SOFA评分也更低(0.00 vs 0.12,p=0.040)。
- 30天时停用组器官功能障碍(SOFA评分≥1)或死亡比例显著更低(11% vs 23%,p=0.017)。
- 机械通气(10% vs 8%,p=0.87)和ICU入住(19% vs 18%,p=0.96)两组无显著差异。
- 作者认为是否继续或停用ACEI/ARB应个体化,综合考虑风险特征、用药指征、替代治疗及门诊监测条件。
适用人群与场景
- 年龄≥18岁、近期有症状的SARS-CoV-2感染、且长期服用ACEI或ARB的患者。
- 研究在奥地利和德国的35个中心开展。
处置流程与药物剂量
- 随机1:1分为停用或继续RAS抑制治疗30天。
研究设计与关键结果
- 研究类型:前瞻性、平行组、随机、对照、开放标签试验;35个中心;样本量204例(停用组n=104,继续组n=100);中位年龄75岁(IQR 66-80),女性37%。
- 主要终点:30天内最大SOFA评分(死亡记为最大可达到的SOFA评分),停用组中位0.00(IQR 0.00-2.00)vs 继续组1.00(IQR 0.00-3.00),p=0.12,无显著差异。
- 30天内死亡:停用组8/104(8%)vs 继续组12/100(12%),p=0.42。
- AUCSOFA:停用组0.00(IQR 0.00-9.25)vs 继续组3.50(IQR 0.00-23.50),p=0.040。
- 平均SOFA评分:停用组0.00(IQR 0.00-0.31)vs 继续组0.12(IQR 0.00-0.78),p=0.040。
- 30天SOFA评分:停用组0.00(10-90百分位数0.00-1.20)vs 继续组0.00(IQR 0.00-24.00),p=0.023。
- 30天时器官功能障碍(SOFA评分≥1)或死亡:停用组11/104(11%)vs 继续组23/100(23%),p=0.017。
- 机械通气:停用组10/104(10%)vs 继续组8/100(8%),p=0.87;ICU入住:停用组20/104(19%)vs 继续组18/100(18%),p=0.96。
证据类型、等级与局限
- 证据类型:前瞻性、平行组、随机、对照、开放标签试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,停用RAS抑制对COVID-19最大严重程度无显著影响,但可能带来更快更好的恢复。
- 作者认为,是否继续或停用应个体化决策,需考虑风险特征、RAS抑制的用药指征、替代治疗的可用性及门诊监测条件。
指南或共识出处
- ACEI-COVID试验,注册号ClinicalTrials.gov NCT04353596,发表于Lancet Respiratory Medicine。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: SARS-CoV-2 entry in human cells depends on angiotensin-converting enzyme 2, which can be upregulated by inhibitors of the renin-angiotensin system (RAS). We aimed to test our hypothesis that discontinuation of chronic treatment with ACE-inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) mitigates the course o\f recent-onset COVID-19.
METHODS: ACEI-COVID was a parallel group, randomised, controlled, open-label trial done at 35 centres in Austria and Germany. Patients aged 18 years and older were enrolled if they presented with recent symptomatic SARS-CoV-2 infection and were chronically treated with ACEIs or ARBs. Patients were randomly assigned 1:1 to discontinuation or continuation of RAS inhibition for 30 days. Primary outcome was the maximum sequential organ failure assessment (SOFA) score within 30 days, where death was scored with the maximum achievable SOFA score. Secondary endpoints were area under the death-adjusted SOFA score (AUCSOFA), mean SOFA score, admission to the intensive care unit, mechanical ventilation, and death. Analyses were done on a modified intention-to-treat basis. This trial is registered with ClinicalTrials.gov, NCT04353596.
FINDINGS: Between April 20, 2020, and Jan 20, 2021, 204 patients (median age 75 years [IQR 66-80], 37% females) were randomly assigned to discontinue (n=104) or continue (n=100) RAS inhibition. Within 30 days, eight (8%) of 104 died in the discontinuation group and 12 (12%) of 100 patients died in the continuation group (p=0·42). There was no significant difference in the primary endpoint between the discontinuation and continuation group (median [IQR] maximum SOFA score 0·00 (0·00-2·00) vs 1·00 (0·00-3·00); p=0·12). Discontinuation was associated with a significantly lower AUCSOFA (0·00 [0·00-9·25] vs 3·50 [0·00-23·50]; p=0·040), mean SOFA score (0·00 [0·00-0·31] vs 0·12 [0·00-0·78]; p=0·040), and 30-day SOFA score (0·00 [10-90th percentile, 0·00-1·20] vs 0·00 [0·00-24·00]; p=0·023). At 30 days, 11 (11%) in the discontinuation group and 23 (23%) in the continuation group had signs of organ dysfunction (SOFA score ≥1) or were dead (p=0·017). There were no significant differences for mechanical ventilation (10 (10%) vs 8 (8%), p=0·87) and admission to intensive care unit (20 [19%] vs 18 [18%], p=0·96) between the discontinuation and continuation group.
INTERPRETATION: Discontinuation of RAS-inhibition in COVID-19 had no significant effect on the maximum severity of COVID-19 but may lead to a faster and better recovery. The decision to continue or discontinue should be made on an individual basis, considering the risk profile, the indication for RAS inhibition, and the availability of alternative therapies and outpatient monitoring options.
FUNDING: Austrian Science Fund and German Center for Cardiovascular Research.
参考来源
- Bauer A, Schreinlechner M, Sappler N, et al. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. Lancet Respir Med. 2021. PMID: 34126053. doi:10.1016/S2213-2600(21)00214-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。